Global Indolent Lymphoma Therapeutics Development Pipeline Review 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Indolent Lymphoma - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Indolent Lymphoma Overview
  3. Therapeutics Development
  4. Pipeline Products for Indolent Lymphoma - Overview
  5. Pipeline Products for Indolent Lymphoma - Comparative Analysis
  6. Indolent Lymphoma - Therapeutics under Development by Companies
  7. Indolent Lymphoma - Therapeutics under Investigation by Universities/Institutes
  8. Indolent Lymphoma Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Indolent Lymphoma - Products under Development by Companies
  13. Indolent Lymphoma - Products under Investigation by Universities/Institutes
  14. Indolent Lymphoma - Companies Involved in Therapeutics Development
  • AbbVie Inc.
  • Affimed Therapeutics AG
  • Altor BioScience Corporation
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Biothera, Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • Infinity Pharmaceuticals, Inc.
  • Juno Therapeutics Inc.
  • Kite Pharma, Inc.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Merck KGaA
  • Millennium Pharmaceuticals, Inc.
  • MorphoSys AG
  • Trillium Therapeutics Inc.

For more information visit http://www.researchandmarkets.com/research/qmrgwx/indolent_lymphoma

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716